| FDA New, GMP Do Clinical Phase II, III Intermediates GMP Custom synthesis, Full Document R&D Center: 8000 sq, More than 100 hoods Pilot Plant: 20000sq, 40 reactors from 5-200L Manufacturing Site: 800000sq, 40 reactors from 100-5000L Web: www.eosmedchem.com Email: info@eosmedchem.com; eosmedchem@gmail.com This is my R&D youtube: https://youtu.be/r5cJdXKNXHk |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 364-76-1, stock 519.8g, white powder, assay by HPLC 99.2%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 6264-67-1, stock 612.9g, white powder, assay by HPLC 98.9%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 87-13-8, stock 243.1g, white powder, assay by HPLC 99.8%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 96567-75-8, stock 268.8g, white powder, assay by HPLC 99.7%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 75001-55-7, stock 597.1g, white powder, assay by HPLC 98.2%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 75001-63-7, stock 466.6g, white powder, assay by HPLC 99.1%, HNMR, LCMS we supply. |
| Irloxacin, 91524-15-1, Irloxacin Intermediate 696-59-3, stock 883.2g, white powder, assay by HPLC 99.4%, HNMR, LCMS we supply. |
0 Comments